Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C. J., Chung, L. W. K., Hsieh, J., Tu, S., & Campbell, M. L. (1992) · PubMed · Cited by 1,049
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
Self-citationVeldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundMyc-driven murine prostate cancer shares molecular features with human prostate tumors
Ellwood-Yen, K., Graeber, T. G., Wongvipat, J., Iruela-Arispe, M. L., Zhang, J., Matusik, R., Thomas, G. V., & Sawyers, C. L. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00197-1 · Cited by 816 · cited 1×
“Newer transgenic or knockout models of mouse prostate cancer may provide an opportunity to address this question in a 'cleaner' experimental syste”
BackgroundSelf-citationKousteni, S. (2001) · Cell · doi:10.1016/s0092-8674(02)08100-x · Cited by 746
Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., & Wilson, E. M. (2001) · PubMed · Cited by 708
Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.
Taplin, M., Bubley, G. J., Ko, Y., Small, E. J., Upton, M. P., Rajeshkumar, B. R., & Balk, S. P. (1999) · PubMed · Cited by 674
Formation of the Androgen Receptor Transcription Complex
Shang, Y., Myers, M., & Brown, M. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00471-9 · Cited by 672 · cited 1×
“, and that androgen induces growth arrest or apoptosis in certain context”
BackgroundMigliaccio, A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.20.5406 · Cited by 672
Raffo, A. J., Perlman, H., Chen, M., Day, M. L., Streitman, J., & Buttyan, R. (1995) · PubMed · Cited by 627
Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor
Matias, P. M., Donner, P., Coelho, R., Thomaz, M., Peixoto, C., Macedo, S., Otto, N., Joschko, S., Scholz, P., Wegg, A., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004571200 · Cited by 608
Baek, S. H., Ohgi, K. A., Rose, D. W., Koo, E. H., Glass, C. K., & Rosenfeld, M. G. (2002) · Cell · doi:10.1016/s0092-8674(02)00809-7 · Cited by 558 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundSelf-citationManolagas, S. C. (2002) · Recent Progress in Hormone Research · doi:10.1210/rp.57.1.385 · Cited by 517 · cited 1×
“Thus, the previously reported nongenotropic effects of androgen receptor on bone growth and prostate cancer cell surviva”
Background(2001) · PubMed · Cited by 500
Sack, J. S., Kish, K. F., Wang, C., Attar, R. M., Kiefer, S. E., An, Y., Wu, G. Y., Scheffler, J. E., Salvati, M. E., Krystek, S. R., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081565498 · Cited by 491
Tremblay, A., Tremblay, G. B., Labrie, F., & Giguère, V. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80479-7 · Cited by 464
AIB1 Is a Conduit for Kinase-Mediated Growth Factor Signaling to the Estrogen Receptor
Font de Mora, J., & Brown, M. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.14.5041-5047.2000 · Cited by 432
Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer
Edwards, J., Krishna, N. S., Grigor, K. M., & Bartlett, J. M. S. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601127 · Cited by 424 · cited 1×
“This finding is likely to have clinical relevance, based on surveys of androgen receptor levels in patient materia”
BackgroundKlein, K. A., Reiter, R. E., Redula, J., Moradi, H., Zhu, X. L., Brothman, A. R., Lamb, D. J., Marcelli, M., Belldegrun, A., Witte, O. N., et al. (1997) · Nature Medicine · doi:10.1038/nm0497-402 · Cited by 399 · cited 1×
“All hormone-refractory sublines were derived directly from their hormone-sensitive parental lines by passaging in castrated mice, and were compared with hormone-sensitive tumors of similar passage numbers in intact mic”
BackgroundSelf-citationPeptide Antagonists of the Human Estrogen Receptor
Norris, J. D., Paige, L. A., Christensen, D. J., Chang, C.-Y., Huacani, M. R., Fan, D., Hamilton, P. T., Fowlkes, D. M., & McDonnell, D. P. (1999) · Science · doi:10.1126/science.285.5428.744 · Cited by 373 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundTaplin, M.-E., Rajeshkumar, B., Halabi, S., Werner, C. P., Woda, B. A., Picus, J., Stadler, W., Hayes, D. F., Kantoff, P. W., Vogelzang, N. J., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.102 · Cited by 364
Androgen Receptor Phosphorylation
Gioeli, D., Ficarro, S. B., Kwiek, J. J., Aaronson, D., Hancock, M., Catling, A. D., White, F. M., Christian, R. E., Settlage, R. E., Shabanowitz, J., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m204131200 · Cited by 351
Craft, N. A., Chhor, C. M., Tran, C., Belldegrun, A. S., deKernion, J. B., Witte, O. N., Said, J. W., Reiter, R. E., & Sawyers, C. L. (1999) · PubMed · Cited by 331
Self-citationZhou, Z. X., Sar, M., Simental, J. A., Lane, M. V., & Wilson, E. M. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)36806-0 · Cited by 312
Androgen receptor as a target in androgen-independent prostate cancer
Balk, S. P. (2002) · Urology · doi:10.1016/s0090-4295(02)01593-5 · Cited by 264
CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma.
Wainstein, M. A., He, F., Robinson, D. R., Kung, H., Schwartz, S., Giaconia, J. M., Edgehouse, N. L., Pretlow, T. P., Bodner, D. R., & Kursh, E. D. (1994) · PubMed · Cited by 244
Masiello, D., Cheng, S., Bubley, G. J., Lu, M. L., & Balk, S. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203310200 · Cited by 240
Androgen-repressed phenotype in human prostate cancer
Zhau, H. Y. E., Chang, S.-M., Chen, B.-Q., Wang, Y., Zhang, H., Kao, C., Sang, Q. A., Pathak, S. J., & Chung, L. W. K. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15152 · Cited by 231 · cited 1×
“, and that androgen induces growth arrest or apoptosis in certain context”
BackgroundKinoshita, H., Shi, Y., Sandefur, C., Meisner, L. F., Chang, C., Choon, A., Reznikoff, C., Bova, G. S., Friedl, A., & Jarrard, D. F. (2000) · PubMed · Cited by 194
Transcriptional programs activated by exposure of human prostate cancer cells to androgen
DePrimo, S. E., Diehn, M., Nelson, J. B., Reiter, R. E., Matese, J., Fero, M., Tibshirani, R., Brown, P. O., & Brooks, J. D. (2002) · Genome Biology · doi:10.1186/gb-2002-3-7-research0032 · Cited by 193 · cited 1×
“2 online), including the well-known PSA and kallikrein-2 ( KLK2”
Ellis, W. J., Vessella, R. L., Buhler, K. R., Bladou, F., True, L. D., Bigler, S. A., Curtis, D., & Lange, P. H. (1996) · PubMed · Cited by 153
Self-citationHeterogeneous Expression and Functions of Androgen Receptor Co-Factors in Primary Prostate Cancer
Li, P., Yu, X., Ge, K., Melamed, J., Roeder, R. G., & Wang, Z. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64422-7 · Cited by 137
Grad, J. M., Dai, J. L., Wu, S., & Burnstein, K. L. (1999) · Molecular Endocrinology · doi:10.1210/me.13.11.1896 · Cited by 135
Schellhammer, P. F., Venner, P. M., Haas, G. P., Small, E. J., Nieh, P. T., Seabaugh, D. R., Patterson, A. L., Klein, E. A., Wajsman, Z., Furr, B. J. A., et al. (1997) · The Journal of Urology · doi:10.1016/s0022-5347(01)64846-8 · Cited by 97 · cited 1×
“About 30% of men whose disease progresses during treatment with androgen receptor antagonists experience a paradoxical fall in serum PSA levels when the antagonist is discontinued, called antiandrogen withdrawal syndrom”
BackgroundMatias, P. M., Carrondo, M. A., Coelho, R., Thomaz, M., Zhao, X.-Y., Wegg, A., Crusius, K., Egner, U., & Donner, P. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm011072j · Cited by 86 · cited 1×
“A subset of these AR mutations map to the ligand-binding domain (LBD) and are proposed to cause resistance by altering the response of the receptor such that noncanonical ligands such as estrogen or hydrocortisone, or even androgen receptor antagonists such as flutamide, behave as agonist”
BackgroundChromosomal aberrations in prostate cancer xenografts detected by comparative genomic hybridization
Laitinen, S., Karhu, R., Sawyers, C. L., Vessella, R. L., & Visakorpi, T. (2002) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.10097 · Cited by 45 · cited 1×
“But can this simple model for hormone-refractory progression be reconciled with previous work implicating other mechanisms? AR gene amplification could result in increased androgen receptor levels, but this occurs in a minority of patients and cannot be invoked as the explanation for our xenograft findings, as there w…”
BackgroundSelf-citationAR Possesses an Intrinsic Hormone-Independent Transcriptional Activity
Huang, Z.-Q. (2002) · Molecular Endocrinology · doi:10.1210/me.16.5.924 · Cited by 41
Lobaccaro, J. A., Poujol, N., Chiche, L., Lumbroso, S., Brown, T. R., & Sultan, C. (1996) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(95)03709-8 · Cited by 38
Cited by
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
“We performed hierarchical clustering using an AR-activated gene signature (28) on the training and validation TNBC tumor data sets.”
MethodIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701
“Common Genomic Alterations in Androgen Receptor Signaling Pathway Members We also conducted a core pathway analysis of AR, which is essential for growth and differentiation of the normal prostate and is responsible for treatment failure in castration-resistant, metastatic disease (Chen et al., 2004; Tran et al., 2009).”
MethodSelf-citationEnzalutamide in Metastatic Prostate Cancer before Chemotherapy
Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., Iversen, P., Bhattacharya, S., Carles, J., Chowdhury, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405095 · Cited by 3,028
“Any cardiac adverse event 88 (10) 24 (3) 66 (8) 18 (2)”
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.